Table 4 First-line and second-line chemotherapy regimens used in patients with CUP.
From: Real-world data analysis of patients with cancer of unknown primary
Chemotherapy regimen | n (%) |
|---|---|
First-line (n = 132) | |
FP (5-FU, cisplatin) | 74 (56.1) |
EP (etoposide, cisplatin) | 20 (15.2) |
PC (paclitaxel, carboplatin) | 13 (9.8) |
Clinical trial | 4 (3.0) |
GP (gemcitabine, cisplatin) | 3 (2.3) |
VIP (cisplatin, etoposide, ifosfamide) | 3 (2.3) |
EC (etoposide, carboplatin) | 2 (1.5) |
FEP (5-FU, etoposide, cisplatin) | 2 (1.5) |
FOLFIRI (5-FU, leucovorin, irinotecan) | 1 (0.8) |
FOLFOX (5-FU, leucovorin, oxaliplatin) | 1 (0.8) |
TP (carboplatin, cisplatin) | 1 (0.8) |
Othersa | 8 (6.1) |
Second-line (n = 69) | |
PC (paclitaxel, carboplatin) | 12 (17.4) |
GP (gemcitabine, cisplatin) | 11 (15.9) |
CAV (cyclophosphamide, doxorubicin, vincristine) | 9 (13.0) |
FP (5-FU, cisplatin) | 7 (10.1) |
CYVADIC (cyclophosphamide, vincristine, doxorubin, dacarbazine) | 5 (7.2) |
Paclitaxel | 4 (5.8) |
Docetaxel | 3 (4.3) |
FOLFOX (5-FU, leucovorin, oxaliplatin) | 3 (4.3) |
CAP (cyclophosphamide, doxorubicin, cisplatin) | 2 (2.9) |
EP (etoposide, paclitaxel) | 2 (2.9) |
Pembrolizumab | 1 (1.4) |
Entrectinib | 1 (1.4) |
Othersb | 9 (13.0) |
